Top Research Reports for Northrop Grumman, BNY Mellon & Celgene
Wednesday, September 20, 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Northrop Grumman (NOC), Bank of New York Mellon (BK) and Celgene (CELG). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-rated Northrop continues to enjoy strong presence in Air Force, Space & Cyber Security programs. Moreover, its product innovation and focus on strengthening its ISR wing will help maintain a stable earnings stream amid the rapidly changing needs of the defense landscape. The company maintains a strong balance sheet and steady cash flow that offer substantial financial flexibility.
To this end, apart from paying solid dividends to its shareholders, Northrop also follows a share buyback policy to maintain a disciplined cash deployment strategy. Also, recent budgetary amendments made by the Trump administration have been in favor of defense biggies like Northrop. However, too much dependence on fixed-price contracts remains a concern for the stock.
(You can read the full research report on Northrop here >>>).
BNY Mellon's shares have outperformed the industry in the last six months (+12.1% vs. +6.8%). The performance was supported by the company’s decent earnings surprise history. It surpassed the Zacks Consensus Estimate for earnings in two of the trailing four quarters. The company’s easing margin pressure (driven by gradual rise in interest rates), potential lesser regulations and rising loan demand are expected to aid top-line growth.
Also, the company’s cost-saving initiatives are likely to improve profitability in the quarters ahead. However, concentration risk arising from significant dependence on fee-based income remains a matter of concern in the near term.
(You can read the full research report on BNY Mellon here >>>).
Shares of Celgene have outperformed the industry in the year so far, gaining (+24% vs. +15.3%). Celgene’s Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. The consecutive increase in annual earnings guidance is also a positive.
Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. The approval of Idhifa in the U.S. for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue while Abraxane sales are under competitive pressure.
(You can read the full research report on Celgene here >>>).
Other noteworthy reports we are featuring today include Anthem (ANTM), Johnson & Johnson (JNJ) and Colgate-Palmolive (CL).
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Orbital ATK Buyout Deal Worth $9.2B to Aid Northrop (NOC)
Rising Margins Aid BNY Mellon (BK), Concentration Risk a Woe
Celgene's (CELG) Revlimid Looks Solid, Abraxane Under Pressure
Featured Reports
POSCO (PKX) to Gain From High Steel Demand, High Debt A Risk
Per the Zacks Analyst, POSCO (PKX) is poised to gain from 1.7% growth in global steel demand. However, high debt levels might raise financial obligations.
Skyworks (SWKS) Battered on Escalating Operating Expenses
Per the Zacks analyst, heavy investments in product development and escalating operating expenses have kept margins under pressure.
Public Storage (PSA) Gains from Buyouts, Supply Woes Remain
Per the Zacks Analyst, Public Storage is poised to gain from high-brand value and strategic acquisitions. However, rising supply remains a concern.
Deutsche Bank's (DB) Cost-Saving Efforts to Drive Efficiency
Per the Zacks analyst, Deutsche Bank's cost saving measures to drive operational efficiency are encouraging. Also, it remains focused to neutralize higher legal costs impact in the upcoming quarters.
FirstEnergy (FE) Gains as it Invests in Regulated Operation
Per the Zacks analyst, FirstEnergy (FE) is gaining from its ambitious "Energizing the Future" plan which aims at expanding its regulated transmission capabilities.
Diversification into Fiber Network Boosts Crown Castle (CCI)
Per the Zacks Analyst, Crown Castle's ongoing efforts to diversify its business from being a tower operator into a fiber provider looks impressive.
Strong Contract Vehicle Assembly Service Bolster Magna (MGA)
Per the Zacks analyst, winning the contract to produce Jaguar Land Rover's E-PACE model at the assembly facility in Graz, Austria strengthens Magna's leadership position in contract manufacturing.
New Upgrades
Sherwin-Williams (SHW) Gains from Valspar Buyout, Cost Cuts
The Zacks analyst thinks that Sherwin-Williams is well placed to gain from synergies of the Valspar acquisition. Its actions to cut operating costs should also lend support to its margins.
Anthem's (ANTM) Premiums, Investment Income Boost Top Line
The Zacks analyst believes that Anthem's consistent revenue growth on the back of rising premium income and investment income continues to boost its margins.
United Rentals (URI) to Gain From Project XL Initiatives
The Zacks analyst stresses that United Rentals is focused on the implementation of Project XL, which is intended to drive profitable growth through a combination of revenue and cost initiatives.
New Downgrades
Soft Global Unit Volumes to Hurt Colgate's (CL) Top Line
Per the Zacks analyst, soft global unit volumes hurt Colgate's top-line in the second quarter. Volumes are likely to remain weak in the second half, as evident from the lowered organic sales view.
J&J's (JNJ) Top-Line under Pressure amid Several Headwinds
Generic competition to key drugs, pricing pressure, soft global market conditions, declining HCV sales and sluggish growth in the Consumer unit are pressurizing J&J's top-line, says the Zacks analyst.
Delta (DAL) Stung by Higher Fuel Costs and Soft Yields
The Zacks analyst is concerned about headwinds like soft yields and escalated fuel costs hurting Delta. Consequently, the company has trimmed its current-quarter unit revenue view.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Northrop Grumman Corporation (NOC) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Colgate-Palmolive Company (CL) : Free Stock Analysis Report
Celgene Corporation (CELG) : Free Stock Analysis Report
Bank Of New York Mellon Corporation (The) (BK) : Free Stock Analysis Report
Anthem, Inc. (ANTM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
